Related Experiment Video

Updated: Mar 8, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

[Cell cycle inhibitors in endocrine receptor positive breast cancer]

Marie-Paule Sablin1, Francesco Ricci1, Delphine Loirat1

  • 1Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

Bulletin Du Cancer
|January 28, 2017
PubMed

Insights

Targeting cell cycle dysregulation with cyclin-dependent kinase (CDK) 4/6 inhibitors shows promise in treating cancer. These drugs, including palbociclib and ribociclib, improve outcomes for metastatic breast cancer patients when combined with endocrine therapy.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Cell cycle dysregulation is a hallmark of cancer, making it a critical therapeutic target.
  • Selective cyclin-dependent kinase (CDK) 4 and 6 inhibitors have re-emerged as a promising therapeutic strategy after earlier pan-inhibitor failures.

Purpose of the Study:

  • To review the development and clinical evaluation of selective CDK4/6 inhibitors for cancer treatment.
  • To highlight the efficacy of palbociclib, ribociclib, and abemaciclib in preclinical and clinical settings.

Main Methods:

  • Review of preclinical data in luminal breast cancer models.
  • Analysis of clinical trial results for CDK4/6 inhibitors.
  • Evaluation of combination therapy with endocrine agents and monotherapy.

Main Results:

  • Palbociclib, ribociclib, and abemaciclib demonstrated preclinical activity in luminal breast cancer.
  • Clinical studies show improved prognosis for metastatic breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy (palbociclib, ribociclib) or as monotherapy (abemaciclib).

Conclusions:

  • Selective CDK4/6 inhibitors represent a valuable therapeutic advance in oncology.
  • Ongoing research and biomarker individualization are crucial for optimizing patient selection and treatment strategies.
Keywords:
AbemaciclibBreast cancerCDK4/6 inhibitorsCancer du seinCellular cycleCycle cellulaireInhibiteurs de CDK4/6PalbociclibRibociclib

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
136.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K